Bicocca Open Archive

Logo unimib boa
CORTINOVIS, DIEGO LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.732
EU - Europa 3.213
AS - Asia 1.483
SA - Sud America 13
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 10.457
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.657
IE - Irlanda 686
IT - Italia 671
SG - Singapore 562
DE - Germania 525
RU - Federazione Russa 434
HK - Hong Kong 428
SE - Svezia 359
CN - Cina 329
UA - Ucraina 151
GB - Regno Unito 110
CA - Canada 74
FI - Finlandia 72
AT - Austria 66
ID - Indonesia 42
IN - India 41
DK - Danimarca 38
FR - Francia 26
NL - Olanda 24
TR - Turchia 24
BE - Belgio 20
JP - Giappone 19
VN - Vietnam 19
BR - Brasile 11
PL - Polonia 11
CZ - Repubblica Ceca 6
IR - Iran 5
EU - Europa 4
KR - Corea 3
TW - Taiwan 3
AU - Australia 2
CL - Cile 2
GR - Grecia 2
JO - Giordania 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
BD - Bangladesh 1
BG - Bulgaria 1
CH - Svizzera 1
ET - Etiopia 1
GN - Guinea 1
HR - Croazia 1
HU - Ungheria 1
IQ - Iraq 1
MD - Moldavia 1
NG - Nigeria 1
PR - Porto Rico 1
RO - Romania 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
Totale 10.457
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.270
Dublin 665
Fairfield 533
Singapore 473
Hong Kong 424
Woodbridge 411
Frankfurt am Main 368
Chandler 360
Ashburn 314
Wilmington 302
New York 265
Houston 231
Seattle 212
Cambridge 208
Jacksonville 168
Milan 162
Princeton 146
Santa Clara 126
Dearborn 125
Shanghai 75
Lawrence 66
Vienna 64
Altamura 57
Nanjing 47
Boardman 45
San Diego 44
Jakarta 42
Turin 41
London 37
Helsinki 36
Beijing 32
Guangzhou 30
Andover 25
Lachine 25
Rome 25
Toronto 24
Brussels 20
Ottawa 16
Hebei 15
Tianjin 15
Assago 14
Dong Ket 14
Munich 14
Pune 14
Dallas 13
Falls Church 13
Jinan 13
Los Angeles 13
Nanchang 12
Chicago 11
Moscow 11
Shenyang 11
Bergamo 10
Hangzhou 10
Norwalk 10
Bologna 9
Lappeenranta 9
Lissone 9
Tokyo 9
Amsterdam 8
Genoa 8
Lodi 8
Edmonton 7
Fremont 7
Monza 7
São Paulo 7
Bari 6
Bonndorf 6
Cesano Maderno 6
Changsha 6
Huizen 6
Mountain View 6
Ningbo 6
Redmond 6
Torre Del Greco 6
Zhengzhou 6
Brno 5
Carate Brianza 5
Carignano 5
Hefei 5
Lodz 5
Phoenix 5
Segrate 5
Torino 5
Alessandria 4
Dongguan 4
Groningen 4
Jiaxing 4
Kunming 4
Naples 4
New Bedfont 4
Perugia 4
Reston 4
Romola 4
Verona 4
Alcamo 3
Antwerp 3
Baltimore 3
Broni 3
Camogli 3
Totale 7.974
Salva come PNG Salva come JPEG
Nome #
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma 316
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 249
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 246
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 230
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 229
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 218
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 211
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases 203
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience 202
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 182
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 182
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 175
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 175
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 174
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 174
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 166
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 166
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 165
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 161
The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT 160
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients 156
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 154
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 153
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 152
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 152
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer 151
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 149
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 146
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 144
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 143
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 143
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 141
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 135
When progressive dysphagia could be related to an “old friend” – a case report 134
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 132
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 124
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 122
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 121
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 111
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 110
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 109
Novel cytotoxic chemotherapies in small cell lung carcinoma 107
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 100
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 99
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 90
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 88
ALK determination: Liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case [Determinazione di ALK: Tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso] 87
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 83
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 80
Focus on nivolumab in NSCLC 80
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 76
Oxaliplatin doublets in non-small cell lung cancer: A literature review 73
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 73
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 73
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 71
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 69
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 66
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 64
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 64
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 61
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 61
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 61
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 60
Isolated cardiac metastasis from squamous cell esophageal cancer 58
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 57
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 55
What are the options for non-small-cell lung cancer patients post second-line therapy? 53
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 52
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus 52
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer 52
Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: From ALK positivity detection to treatment strategies after relapse 51
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 51
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: A literature review 51
Targeted therapies and immunotherapy in non-small-cell lung cancer 49
Treatment patterns, clinical outcomes and healthcare costs of advanced non-small cell lung cancer: A real-world evaluation in Italy 48
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 46
Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer after linear accelerator-based stereotactic radiosurgery for solitary brain metastasis 45
VITAMIN D SUPPLEMENTATION MAY IMPROVE COVID-19 PROGNOSIS? EVIDENCE FROM A SYSTEMATIC REVIEW AND META-ANALYSIS 42
Economic assessment of NGS testing workflow for NSCLC in a healthcare setting 41
Interpretation of lung cancer study outcomes 40
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons 37
Integrated therapeutic strategies for anaplastic thyroid carcinoma 36
Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold 35
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma 34
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer 32
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 32
Project R. Evolution for improving clinical research in Italy: challenges and strategies 32
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma 31
Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer 30
Comment on: "is there a role for Vitamin D in human reproduction?" 30
Pulmonary carcinoid tumours: indolent but not benign 29
RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center 29
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 28
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database 28
A new race against lung cancer 27
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer 26
Metastatic melanoma 26
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders 25
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues 24
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group 23
Totale 9.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.685
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.685
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.298 0 0 0 88 102 155 196 264 214 118 128 33
2020/20211.499 76 62 151 133 87 94 152 178 142 155 126 143
2021/20221.108 102 144 159 114 64 77 50 42 55 58 82 161
2022/20231.743 211 504 138 184 112 244 24 117 113 39 43 14
2023/20242.515 45 44 45 64 588 530 444 77 309 57 47 265
2024/20251.364 312 712 289 51 0 0 0 0 0 0 0 0
Totale 11.214